 |
 |
Hodgkin lymphoma is one of two major categories of lymphoma. It is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. A defining attribute of the Reed-Sternberg cell is its expression of the CD30 antigen. According to the American Cancer Society, more than 8,800 people will be diagnosed with Hodgkin lymphoma in the United States during 2011.
Randomized, double-blind trial evaluating brentuximab vedotin versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant
Evaluating the potential for retreatment with brentuximab vedotin in patients who have relapsed after discontinuing previous brentuximab vedotin therapy
Evaluating the safety of brentuximab vedotin in combination with multi-agent chemotherapy in newly diagnosed Hodgkin lymphoma patients; enrollment to this trial is complete
If you have questions about the Hodgkin lymphoma clinical trials, please e-mail Seattle Genetics at clinicaltrials@seagen.com. Additional information about cancer, lymphoma and participating in clinical trials can be found on the following web sites.